EPHA2 and breast carcinoma: Similarly, the EphA2-conjugated paclitaxel (PTXEphA2) loaded microspheres reduced the viability of the MDA-MB_231 breast cancer cells than the unconjugated paclitaxel (PTX)-loaded microspheres (p < 0.05) after 72 and 96 h.